Immunotherapy for Prostate Cancer: Where We Are Headed

Immunotherapy for Prostate Cancer: Where We Are Headed

Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has bec...

Full description

Bibliographic Details
Main Authors: Giuseppe Schepisi, Alberto Farolfi, Vincenza Conteduca, Filippo Martignano, Delia De Lisi, Giorgia Ravaglia, Lorena Rossi, Cecilia Menna, Salvatore Roberto Bellia, Domenico Barone, Roberta Gunelli, Ugo De Giorgi
Format: Article
Language:English
Published: MDPI AG 2017-12-01
Series:International Journal of Molecular Sciences
Subjects:
prostate cancer
immunotherapy
vaccines
CTLA4
PD1
PD-L1
antibodies
Online Access:https://www.mdpi.com/1422-0067/18/12/2627

Internet

https://www.mdpi.com/1422-0067/18/12/2627

Similar Items